Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults

Diabetes, Obesity and Metabolism

Volumn 9, Issue 1, 2007, Pages 11-22

  Yuen, K C J ^a   Dunger, D B ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Growth hormone; Growth hormone deficient adults; Insulin sensitivity; Insulin like growth factor I; Metabolic syndrome

Indexed keywords

ACIPIMOX; ANTIDIABETIC AGENT; GLUCOSE; GROWTH HORMONE; HYPOPHYSIS HORMONE; INSULIN SENSITIZING AGENT; OCTREOTIDE; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 3 SOMATOMEDIN C COMPLEX; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ACROMEGALY; BIOAVAILABILITY; BODY COMPOSITION; CELL FUNCTION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENTIATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HIGH RISK PATIENT; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; LIPOLYSIS; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONSET AGE; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33845541643     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00591.x     Document Type: Review

References (90)

1. Rosenfalck AM, Maghsoudi S, Fisker S et al. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 2000; 85: 4173-4181.
2. Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab 2003; 88: 1455-1463.
3. Eden Engstrom B, Burman P, Holdstock C, Karlsson FA. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab 2003; 88: 5193-5198.
4. Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf) 2005; 63: 310-316.
5. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 2005; 152: 67-75.
6. Spina LD, Soares DV, Brasil RR et al. Glucose metabolism and visceral fat in GH deficient adults: 1 year of GH replacement. Growth Horm IGF Res 2004; 14: 45-51.
7. Spina LD, Soares DV, Brasil RR, Lobo PM, Lucia Conceicao F, Vaisman M. Glucose metabolism and visceral fat in GH deficient adults: Two years of GH-replacement. Pituitary 2004; 7: 123-129.
8. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995; 16: 3-34.
9. Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith D. Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: Relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes 2003; 52: 2483-2489.
10. Yakar S, Liu JL, Fernandez AM et al. Liver-specific IGF-I gene deletion leads to muscle insulin insensitivity. Diabetes 2001; 50: 1110-1118.
11. Yakar S, Setser J, Zhao H et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 2004; 113: 96-105.
12. Dominici FP, Cifone D, Bartke A, Turyn D. Loss of insulin sensitivity to insulin at early events of the insulin signalling pathway in the liver of growth hormone-transgenic mice. J Endocrinol 1999; 161: 383-392.
13. Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825-836.
14. Daughaday W, Rotwein P. Insulin-like growth factors I and II. peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10: 68-91.
15. LeRoith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53-74.
16. Houssay BA. The hypophysis and metabolism. N Engl J Med 1936; 214: 961-986.
17. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
18. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987; 8: 115-131.
19. Press M. Growth hormone and metabolism. Diabetes Metab Rev 1988; 4: 391-414.
20. Pierluissi J, Campbell J. Metasomatotrophic diabetes and its induction: basal insulin secretion and insulin release responses to glucose, glucagon, arginine and meals. Diabetologia 1980; 18: 223-228.
21. Schwander JC, Hauri C, Zapf J, Froesch ER. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: Dependence on growth hormone status. Endocrinology 1983; 113: 297-305.
22. Baxter RC, Martin JL. Binding proteins for the insulin-like growth factors: Structure, regulation and function. Prog Growth Factor Res 1989; 1: 49-68.
23. Frystyk J, Hussain M, Skjaerbaek C, Porksen N, Froesch ER, Orskov H. The pharmacokinetics of free insulin-like growth factor-I in healthy subjects. Growth Horm IGF Res 1999; 9: 150-156.
24. Frystyk J, Hojlund K, Rasmussen KN, Jorgensen SP, Wildner-Christensen M, Orskov H. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J Clin Endocrinol Metab 2002; 87: 260-266.
25. Dominici FP, Turyn D. Growth hormone-induced alterations in the insulin-signaling system. Exp Biol Med (Maywood) 2002; 227: 149-157.
26. Kaji H, Ohashi S, Abe H, Chihara K. Regulation of the growth hormone (GH) receptor and GH-binding protein mRNA. Proc Soc Exp Biol Med 1994; 206: 257-262.
27. Ho KY, Veldhuis JD, Johnson ML et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 1988; 81: 968-975.
28. Pijl H, Langendonk JG, Burggraaf J et al. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab 2001; 86: 5509-5515.
29. Yuen K, Frystyk J, Umpleby M, Fryklund L, Dunger D. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults. J Clin Endocrinol Metab 2004; 89: 3956-3964.
30. Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 1982; 31: 663-669.
31. Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults. Eur J Endocrinol 2003; 149: 511-519.
32. Moller N, Jorgensen JO, Schmitz O et al. Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol 1990; 258: E86-E91.
33. Gravholt CH, Schmitz O, Simonsen L, Bulow J, Christiansen JS, Moller N. Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am J Physiol 1999; 277: E848-E854.
34. Hansen AP, Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 1970; 6: 27-33.
35. Pal BR, Matthews DR, Edge JA, Mullis PE, Hindmarsh PC, Dunger DB. The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia. Clin Endocrinol (Oxf) 1993; 38: 93-100.
36. Pal BR, Phillips PE, Matthews DR, Dunger DB. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 542-549.
37. Moller N, Porksen N, Ovesen P, Alberti KG. Evidence for increased sensitivity of fuel mobilization to growth hormone during short-term fasting in humans. Horm Metab Res 1993; 25: 175-179.
38. Gillberg P, Bramnert M, Thoren M, Werner S, Johannsson G. Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Growth Horm IGF Res 2001; 11: 273-281.
39. Giavoli C, Porretti S, Ronchi CL et al. Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism 2004; 53: 740-743.
40. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy LJ. The effects of GH replacement in adult GH-deficient patients: Changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf) 2004; 60: 442-450.
41. Bulow B, Link K, Ahren B, Nilsson AS, Erfurth EM. Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol (Oxf) 2004; 61: 683-691.
42. Wilton P. Review of HypoCCS, data. Program of the 83rd Annual Meeting of The Endocrine Society. Denver, CO, 2001;31: S11-31.
43. Wilton P. Review of KIMS data. Program of the 83rd Annual Meeting of The Endocrine Society. Denver, CO, 2001; 31: S11-32.
44. Monson JP, Bengtsson BA, Abs R, Feldt-Rasmussen U, Wuster C. Can growth hormone therapy cause diabetes? KIMS Strategic Committee. Lancet 2000; 355: 1728-1729.
45. Humbel RE. Insulin-like growth factors I and II. Eur J Biochem 1990; 190: 445-462.
46. Steele-Perkins G, Turner J, Edman JC et al. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 1988; 263: 11486-11492.
47. Ullrich A, Gray A, Tam AW et al. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5: 2503-2512.
48. Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol 1991; 260: E846-E851.
49. Sakai K, Lowman HB, Clemmons DR. Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture. J Biol Chem 2002; 277: 13620-13627.
50. Fernandez AM, Kim JK, Yakar S et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001; 15: 1926-1934.
51. Camacho-Hubner C, Woods KA, Clark AJ, Savage MO. Insulin-like growth factor (IGF)-I gene deletion. Rev Endocr Metab Disord 2002; 3: 357-361.
52. Taylor AM, Dunger DB, Grant DB, Preece MA. Somatomedin-C/IGF-I measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls. Diabetes Res 1988; 9: 177-181.
53. Simpson HL, Jackson NC, Shojaee-Moradie F et al. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 425-432.
54. Saukkonen T, Amin R, Williams R et al. Combined recombinant human insulin-like growth factor I/insulin-like growth factor binding protein 3 suppresses growth hormone secretion and improves insulin sensitivity in adolescents with Type 1 diabetes. Proceedings of the 63rd Scientific Sessions of the American Diabetes Association, New Orleans, USA, 2003.
55. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: Evidence for in vivo biological activity. J Clin Endocrinol Metab 2000; 85: 1518-1524.
56. Clemmons DR, Moses AC, Sommer A et al. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 2005; 15: 265-274.
57. Kern PA, Svoboda ME, Eckel RH, Van Wyk JJ. Insulinlike growth factor action and production in adipocytes and endothelial cells from human adipose tissue. Diabetes 1989; 38: 710-717.
58. Kunitomi M, Wada J, Takahashi K et al. Relationship between reduced serum IGF-I levels and accumulation of visceral fat in Japanese men. Int J Obes Relat Metab Disord 2002; 26: 361-369.
59. Simpson H, Savine R, Sonksen P et al. Growth hormone replacement therapy for adults: Into the new millennium. Growth Horm IGF Res 2002; 12: 1-33.
60. Tomlinson JW, Holden N, Hills RK et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357: 425-431.
61. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2121-2127.
62. Yuen KCJ, Frystyk J, White DK et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone dose in adults with severe growth hormone deficiency. Clin Endocrinol (Oxf) 2005; 63: 428-436.
63. Bengtsson BA. The consequences of growth hormone deficiency in adults. Acta Endocrinol (Copenh) 1993; 128 (Suppl. 2): 2-5.
64. Johansson JO, Fowelin J, Landin K, Lager I, Bengtsson BA. Growth hormone-deficient adults are insulin-resistant. Metabolism 1995; 44: 1126-1129.
65. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803.
66. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72: 51-59.
67. Johannsson G, Marin P, Lonn L et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82: 727-734.
68. Albert SG, Mooradian AD. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J Clin Endocrinol Metab 2004; 89: 695-701.
69. Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: A 12-month placebo-controlled trial. J Clin Endocrinol Metab 2005; 90: 1466-1474.
70. Yuen K, Wareham N, Frystyk J et al. Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: Effects on beta-cell function and post-load glucose tolerance. Eur J Endocrinol 2004; 151: 39-45.
71. Jallad RS, Liberman B, Vianna CB, Vieira ML, Ramires JA, Knoepfelmacher M. Effects of growth hormone replacement therapy on metabolic and cardiac parameters, in adult patients with childhood-onset growth hormone deficiency. Growth Horm IGF Res 2003; 13: 81-88.
72. Knoepfelmacher M, Jallad RS, Liberman B. Absence of effects of long-term growth hormone replacement therapy on insulin sensitivity in adults with growth hormone deficiency of childhood-onset (GHDA-CO). Growth Horm IGF Res 2003; 13: 295-302.
73. Underwood LE, Attie KM, Baptista J. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: A two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003; 88: 5273-5280.
74. Cheetham TD, Holly JM, Clayton K, Cwyfan-Hughes S, Dunger DB. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type 1 diabetes. Diabet Med 1995; 12: 885-892.
75. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199-1204.
76. Cheetham TD, Connors M, Clayton K, Watts A, Dunger DB. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I). Clin Endocrinol (Oxf) 1997; 46: 415-424.
77. Quattrin T, Thrailkill K, Baker L et al. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 1997; 20: 374-380.
78. Acerini CL, Harris DA, Matyka KA et al. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism 1998; 47: 1481-1489.
79. Crowne EC, Samra JS, Cheetham T, Watts A, Holly JM, Dunger DB. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus. Metabolism 1998; 47: 31-38.
80. Carroll PV, Umpleby M, Alexander EL et al. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: Effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clin Endocrinol (Oxf) 1998; 49: 739-746.
81. Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. Rhigf-I in IDDM Study Group. Diabetes Care 1999; 22: 585-592.
82. Thrailkill KM, Fowlkes JL, Hyde JF, Litton JC. The effects of co-therapy with recombinant human insulin-like growth factor I and insulin on serum leptin levels in adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2001; 2: 25-29.
83. Quattrin T, Thrailkill K, Baker L, Kuntze J, Compton P, Martha P. Improvement of HbA1c without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin. rhIGF-I in IDDM Study Group. J Pediatr Endocrinol Metab 2001; 14: 267-277.
84. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-2241.
85. Schalch DS, Turman NJ, Marcsisin VS, Heffernan M, Guler HP. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1563-1568.
86. Jabri N, Schalch DS, Schwartz SL et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994; 43: 369-374.
87. Young SC, Clemmons DR. Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in noninsulin-dependent diabetics. J Clin Endocrinol Metab 1994; 78: 609-614.
88. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995; 28 (Suppl.): S185-S194.
89. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45: 91-100.
90. Cusi K, DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 2000; 85: 3077-3084.